Jon OggEarnings season is far from over, but roughly three quarters of the stocks in the Standard & Poor’s 500 Index stocks have now reported their earnings for the first calendar quarter of…
British drug maker AstraZeneca once again rejected a takeover bid from U.S. pharmaceutical giant Pfizer, this one worth $106 billion (about £50 a share) in cash and stock.
thinkstockApril 28, 2014: Markets opened higher on Monday with little economic data to drive the market either up or down. Consequently shares fell then rose and look to be headed for small…
The NYSE Arca Biotechnology Index fell nearly 9% between a peak on Jan. 22 and a low on Feb. 5. It jumped 23% over the next three weeks, and then gave it…
In a new research report, the Healthcare team at UBS took an in-depth look at the top companies that are making major advances in cancer therapeutics. Here is the UBS list of…
thinkstockApril 21 2014: Markets opened higher on Monday but there wasn’t a lot of action as the only data out today was leading indicators, and they came in right on estimates. At…
ThinkstockIt is not that common that you hear about mergers in the $50 billion range. But what about when you hear of mergers in the $80 billion or $100 billion range? AstraZeneca…
Canaccord Genuity is one of the few firms that are willing to cover small-cap biotech and emerging pharma stocks. Sometimes the price target upside is off the charts as well. In case…
Jon C. Ogg thinkstockApril 7, 2014: Markets opened lower on Monday and were on a downhill slide all day long. Momentum stocks again had a terrible day. At the close of trading today the DJIA…
While the FDA has been far from a friend to MannKind over the past few years, the latest FDA panel backing may have given diabetes patients and investors some hope. That hope…
ThinkstockWhen the S&P 500 index rises more than 25% in a year, you have to figure that some of the largest U.S. corporations are doing pretty well. And you would be right.…
ThinkstockThe short interest data for the first two weeks of March is out, and the results among the top high-yield safe dividend stocks are mixed. The biggest changes took place in the…
Wikimedia CommonsWith the U.S. pharmaceutical group, and particularly the specialty pharmaceutical names, under pressure over recent trading sessions, the large biotechnology stocks were not the lone rangers when it came to the…
thinkstockMarch 24, 2014: Markets opened slightly higher on Monday but soon took a turn south and spent most of the day solidly down. Biotechs, healthcare, discretionary, and tech stocks were all weaker…
thinkstockMarch 21, 2014: Markets opened higher on Friday but the Nasdaq sank quickly, bounced for a while, and finally settled solidly lower. It took the Dow and the S&P 500 until noon…
